Compare iShares MSCI Indonesia ETF (EIDO) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Cassava Sciences Inc — how do they compare? iShares MSCI Indonesia ETF trades at $11.91 (market cap $409.22M), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: iShares MSCI Indonesia ETF is far larger — about 10.4× Cassava Sciences Inc's market cap, and iShares MSCI Indonesia ETF is more actively traded (879,527 versus 759,018). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Indonesia ETF for 76 Days and Cassava Sciences Inc for 37 Days on average.
| EIDO | FLNA | |
|---|---|---|
Market Cap | $409.22M | $39.40M |
Volume | 879,527 | 759,018 |
52-Week High | $19.22 | $4.64 |
52-Week Low | $10.80 | $0.68 |
Typical Hold Time | 76 Days | 37 Days |
Sector | — | Health |
Enterprise Value | — | -$43.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO trades at $11.87, showing minimal daily movement with a 0.08% gain. Technical indicators signal a bearish trend, with moving averages and ADX pointing downward, though RSI levels hint at potential oversold conditions. Recent news highlights underperformance amid sector rotation away from Asian equities, with volume declining 21% below average. Key financial ratios are unavailable in the provided data, limiting fundamental assessment.
The outlook remains cautious due to weak price action and bearish technicals. Risks include high financials exposure and slow EPS growth. Upside may depend on seasonal trends or valuation support, but current sentiment and institutional flows suggest continued pressure. Investors should weigh technical weakness against potential bargain opportunities.
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
